Study of velzatinib for advanced GIST after multiple prior treatments
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called velzatinib for people with advanced gastrointestinal stromal tumor (GIST) that has spread or cannot be removed by surgery. It is for those whose cancer has worsened after trying several standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have GIST that has spread to other parts of your body or can't be removed with surgery.
- Your cancer has gotten worse after or you couldn't tolerate imatinib, sunitinib, regorafenib, and pimitespib.
- Your tumor's gene mutations (KIT and/or PDGFRA) have been identified.
- You must have a tumor sample from a past biopsy or be willing to have a new biopsy for testing.
- You are willing to use effective birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a newer cancer drug (velzatinib) with a standard treatment (imatinib) for gastrointestinal stromal tumors (GIST) that cannot be surgically removed or have spread. You would receive one of these two drugs to see which works better and is safer.
This trial tests a drug called lenvatinib for people with advanced GIST that has not responded to three previous treatments. It may offer a new option if standard therapies have stopped working or caused severe side effects.
This trial tests a new drug, ziftomenib, combined with imatinib for people with advanced or spreading gastrointestinal stromal tumors (GIST) that have a KIT mutation. It may help if your GIST has gotten worse while on imatinib.
This trial tests whether adding a new drug called CGT9486 to sunitinib (a standard cancer drug) works better than sunitinib alone for gastrointestinal stromal tumors (GISTs) that have grown or spread. You may qualify if your GIST stopped responding to or caused problems with imatinib, an earlier treatment.
This Phase 2 trial tests whether combining rivoceranib with paclitaxel can shrink or control advanced metastatic gastrointestinal stromal tumor (GIST) after standard medicines have stopped working. It may help people whose GIST has progressed despite prior treatments like imatinib, sunitinib, and regorafenib.
This trial studies avapritinib, a targeted medicine, for people with advanced or returning gastrointestinal stromal tumors (GIST) whose tumor does not have PDGFRA exon 18 mutations. It aims to see how well the drug can shrink tumors or control the disease.
Hear when a new Gastrointestinal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.